Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris

25/03/2016 - 2 minutes

This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known for its beauty, bohemian lifestyle and, of course the Eiffel Tower, the Louvre and le baguette, Paris is also the home of OSE Pharma, our Biotech of the Week.

OSE_Phrma_Logo

City: Paris (France)

Founded: 2012

Employees: N/A

Financial Data: €24.3M total raised (as of 01/2016)

CEO: Dominique Costantini

Dominique__Costantini _CEO_OsePharma_Biotech_Week

Mission: OSE Pharma is developing immunotherapy products against invasive/metastatic late-stage cancers. Memopi, one of its key technologies and currently being developed for ovarian, colon and breast cancers.

The treatment helps the patient’s immune system remove malignant cancer cells, by ‘re-educating its immunological memory‘ in order to allow the immune system to attack tumor cells. By doing this, the patient’s cytotoxic T cells increase and are able to respond more efficiently to the cancer.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member